Rutherford, NJ, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and ...
Presenter: Mini Balakrishnan, Ph.D. Date/Time: June 7, 2026, at 12:30 pm – 1:30 pm CT All presentations will be available following the lifting of the embargo on Friday, June 5, 2026, at 6:30 PM CT.
Structure Therapeutics to present promising data on ACCG-2671 for obesity and GLP-1 receptor agonists for Parkinson's at ADA 2025. Structure Therapeutics announced two late-breaking poster ...
At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were ...
A total of eight clinical abstracts for the investigational agent empagliflozin will be presented. Empagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor being investigated for the ...
CCS’s latest evidence-based research reinforces the most innovative and intelligent approaches to improving adherence and outcomes, while reducing the total costs of diabetes care CHICAGO--(BUSINESS ...
GRAND RAPIDS, Mich., June 1, 2026 /PRNewswire/ -- Cirius Therapeutics, Inc., a developer of innovative therapies for people suffering from diseases caused by mitochondrial dysfunction and insulin ...
SAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE)-- Biomea Fusion, Inc. ("Biomea” or "Biomea Fusion” or "the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results